Pleural lavage test to guide surgery in resectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether washing fluid from around the lungs (pleural lavage) can show cancer cells and help predict outcomes for people with operable esophageal cancer. It may add useful information before surgery to support better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed esophageal cancer based on a pathology test (biopsy or similar) before starting treatment.
- Your cancer is considered resectable, meaning surgeons think it can be fully removed (aiming for an R0 resection).
- Your scans show no distant spread (M0) and lymph node status can be N0 to N3.
- You do not have a history of other past cancers (besides the current esophageal cancer).
- You have not had endoscopic scar-removal procedures called ESD or EMR.
- Doctors can safely do the pleural lavage procedure—there should be no lung-covering adhesions that prevent it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study looks back at past patients’ medical and pathology records from esophageal cancer surgeries. It may help improve how doctors understand which advanced tumors should be treated, by reviewing outcomes in specific tumor stages.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.